Crossref
Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors
Clinical Skin Cancer · 2017-12 · 2 (1-2) · 59-65
DOI: 10.1016/j.clsc.2017.11.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Skin Cancer, 2017-12. Verfasst von Sarah E. Fenton und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 97 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Fenton, S. E., Sosman, J. A., & Chandra, S. (2017). Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. Clinical Skin Cancer, 2(1-2), 59-65. https://doi.org/10.1016/j.clsc.2017.11.001
Vancouver
Fenton SE, Sosman JA, Chandra S. Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. Clinical Skin Cancer. 2017;2(1-2):59-65. doi:10.1016/j.clsc.2017.11.001
BibTeX
@article{Fenton2017,
author = {Fenton, Sarah E. and Sosman, Jeffrey A. and Chandra, Sunandana},
title = {Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors},
journal = {Clinical Skin Cancer},
year = {2017},
volume = {2},
number = {1-2},
pages = {59--65},
doi = {10.1016/j.clsc.2017.11.001}
}
EUVIMED